Literature DB >> 7288121

Risk factors for isoniazid (NIH)-induced liver dysfunction.

D S Dickinson, W C Bailey, B I Hirschowitz, S J Soong, L Eidus, M M Hodgkin.   

Abstract

We examined prospectively risk factors which might contribute to INH-induced liver damage in 113 patients taking preventive INH for at least 8 weeks. Twelve who had abnormal initial liver tests did not get worse with INH, while 19/101 with normal initial tests developed significant liver dysfunction, mostly hepatocellular, three having overt hepatitis. When 12 other patients who drank alcohol were excluded from analysis, there were still 15/89 with significant liver dysfunction, 12 of whom were slow acetylators (p less than 0.05). The only other risk factor was age. By combining acetylator phenotype with age, but excluding alcohol, we calculated the risk of INH-induced liver enzyme elevation as follows: under 35 years--fast acetylators, 3.7%, slow acetylators, 13%; over 35--fast acetylators, 13.2%, slow acetylators, 37% (p less than 0.02). Fast acetylation is thus not a risk factor for developing INH-induced liver dysfunction; indeed, the contrary seems to be the case.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7288121     DOI: 10.1097/00004836-198109000-00012

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  13 in total

1.  Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.

Authors:  P Sadaphal; J Astemborski; N M Graham; L Sheely; M Bonds; A Madison; D Vlahov; D L Thomas; T R Sterling
Journal:  Clin Infect Dis       Date:  2001-10-12       Impact factor: 9.079

2.  Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid.

Authors:  E Peretti; G Karlaganis; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.

Authors:  Nicolas Vuilleumier; Michel F Rossier; Alberto Chiappe; Florence Degoumois; Pierre Dayer; Bernadette Mermillod; Laurent Nicod; Jules Desmeules; Denis Hochstrasser
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

4.  Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.

Authors:  S R Salpeter
Journal:  West J Med       Date:  1993-11

5.  NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.

Authors:  Norihide Higuchi; Naoko Tahara; Katsunori Yanagihara; Kiyoyasu Fukushima; Naofumi Suyama; Yuichi Inoue; Yoshitsugu Miyazaki; Tsutomu Kobayashi; Kohichiro Yoshiura; Norio Niikawa; Chun-Yang Wen; Hajime Isomoto; Saburou Shikuwa; Katsuhisa Omagari; Yohei Mizuta; Shigeru Kohno; Kazuhiro Tsukamoto
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

Review 6.  Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation.

Authors:  F J Farrell; E B Keeffe; K M Man; J C Imperial; C O Esquivel
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

7.  Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients.

Authors:  W L Gent; H I Seifart; D P Parkin; P R Donald; J H Lamprecht
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 8.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

9.  Antituberculosis drug-induced hepatotoxicity in children.

Authors:  Peter R Donald
Journal:  Pediatr Rep       Date:  2011-06-16

10.  N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.

Authors:  Ching-Soon Ng; Abul Hasnat; Abdullah Al Maruf; Maizbha Uddin Ahmed; Munir Pirmohamed; Christopher P Day; Guruprasad P Aithal; Ann K Daly
Journal:  Eur J Clin Pharmacol       Date:  2014-06-03       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.